ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

レニオリシブ

Leniolisib

HCID 57495353
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1354690-24-6
標準SMILES
CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1
InChIKey
MWKYMZXCGYXLPL-ZDUSSCGKSA-N
分子式
C21H25F3N6O2
平均分子量
450.5 g/mol
単同位体質量
450.19910855

概要

Leniolisib is a pyridopyrimidine that is 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine substituted by [(3S)-1-propanoylpyrrolidin-3-yl]amino and 6-methoxy-5-(trifluoromethyl)pyridin-3-yl groups at positions 4 and 6, respectively. It has a role as an EC 2.7.1.153 (phosphatidylinositol-4,5-bisphosphate 3-kinase) inhibitor and an immunomodulator. It is a tertiary carboxamide, a member of pyridines, an aromatic ether, an organofluorine compound, a member of pyrrolidines, a pyridopyrimidine and a secondary amino compound.

名称と識別子

優先名称
Leniolisib
IUPAC
1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one
現地名
レニオリシブ
英語名
Leniolisib
分子式
C21H25F3N6O2
分子量
450.46

名称と別名

Leniolisib1354690-24-6Cdz173 free baseCdz-173 free baseCDZ173-NXleniolisibumCDZ-173-NXL22772Z9CP1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-1-((3S)-3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-7,8-dihydro-5H-pyrido(4,3-d)pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-oneRefChem:57738
名称をさらに表示
レニオリシブCDZ 173CS-2818leniolisib(CDZ 173)CDZ173CDZ-173CDZ 173Rupatadine Impurity 2-d8Leniolisib, 10 mM in DMSOleniolisib (CDZ 173) ,S8752inhibit,Inhibitor,Phosphoinositide 3-kinase,Leniolisib,PI3K,CDZ-173,CDZ 173
(S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-oneLeniolisib [INN]Leniolisib free baseMFCD30470232leniolisib (CDZ 173)C21H25F3N6O2Leniolisib (CDZ173)Leniolisib; CDZ173

物性

構造計算による物性補完中

XLogP
2.5
極性表面積
83.5 Ų
水素結合供与体数
1
水素結合受容体数
10
回転可能結合数
5
重原子数
32
形式電荷
0
複雑度
654

実験および物理化学的性質

Solubility<1 mg/mL
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors

EMA approved medicines: Human medicine (Orphan designations)

物理化学的性質

貯蔵温度
-20 °C · Store at -20°C
溶解性
DMF:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.11(Max Conc. mM)DMSO:71.67(Max Conc. mg/mL);159.09(Max Conc. mM)Ethanol:16.5(Max Conc. mg/mL);36.63(Max Conc. mM)
外見
A crystalline solid
色
White to off-white

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Hepatotoxicity · 1 件

In the prelicensure clinical trials of leniolisib in patients with APDS, ALT elevations were rarely described, and there were no reports of hepatic adverse events or discontinuations because of abnormal liver tests. Intermittent elevations in liver enzymes are not uncommon in patients with untreated APDS due to bacterial, viral and opportunistic infections. Since its approval in the United States, there have been no reported cases of clinically apparent liver injury associated with leniolisib therapy, but the drug has had very limited clinical use.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

化学と産業

薬理情報

ATC Code · 2 件

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingLeniolisib is 94.5% bound to plasma proteins.
Pharmacodynamics · 1 件

Leniolisib works to block aberrant PI3Kδ-dependent signalling pathways of immune cells, such as B and T cells, neutrophils, monocytes, basophils, plasmocytoid dendritic cells, and mast cells. _In vitro_, leniolisib dose-dependently suppresses the PI3Kδ pathway hyperactivation in cell lines overexpressing p110δ mutants and in primary immune cells from patients with APDS. _Ex vivo_ pharmacodynamics of leniolisib in the proportion of phosphorylated Akt (pAkt)- positive B cells were assessed intra-individually at 10, 30, and 70 mg twice daily for four weeks at each dose level in patients with APDS. Within the explored dose range, higher leniolisib plasma concentrations were generally associated with a higher reduction of pAkt-positive B cells. Higher doses were associated with a slightly higher peak and more sustained reduction. Treatment with leniolisib 70 mg twice a day at a steady state is estimated to produce a time-averaged reduction of pAkt-positive B cells by approximately 80%.

Mechanism of Action · 1 件

Phosphoinositide-3-kinase δ (PI3Kδ) is a lipid kinase activated downstream of tyrosine kinase receptors and G-protein–coupled receptors in immune cells. It mediates the PI3K/AKT pathway, which is involved in cell proliferation, growth, and survival. A heterodimer made up of a regulatory subunit (p85α) and a catalytic subunit (p110δ), PI3Kδ is primarily expressed on hematopoietic cells such as lymphocytes and myeloid cells. It converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), a signalling molecule that downstream proteins like the AKT kinase, which activate mammalian target of rapamycin (mTOR) complex I and inhibit FOXO family of transcription factors. APDS is associated with gain-of-function variants in the gene encoding p110δ or loss of function variants in the gene encoding p85α, each causing hyperactivity of PI3K-delta, reduced T cell function, lymphadenopathy, and immunodeficiency. Leniolisib inhibits PI3Kδ by blocking the active binding site in the p110δ subunit. In cell-free isolated enzyme assays, the selectivity was higher for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAKT pathway activity and inhibited proliferation and activation of B and T cell subsets. Leniolisib inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and the dysregulation of B and T cells.

関連反応

2 件
反応記録を作成
HRID 242340 の反応式
HRID 242340生成物として
HRID 242341 の反応式
HRID 242341生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
1354690-24-6
PubChem CID
57495353
DTXSID
DTXSID501358746
ChEMBL
CHEMBL3643413
ChEBI
CHEBI:229649
UNII
L22772Z9CP
Biological Half-LifeThe effective half-life is approximately seven hours. The apparent terminal elimination half-life is approximately 10 hours.
Metabolism/Metabolites · 1 件

About 60% of leniolisib is metabolized by the liver. Leniolisib undergoes oxidative metabolism, which is primarily mediated by CYP3A4 (94.5%), as well as CYP3A5 (3.5%), CYP1A2 (0.7%) and CYP2D6 (0.7%) to a minor extent. Few metabolites of leniolisib have been characterized in one study; however, no metabolites were abundant in plasma relative to the parent drug. Other metabolic pathways include dealkylation, demethylation, and hydroxylation. Other suggested excretion routes include intestinal secretion by BCRP and CYP1A1-mediated extrahepatic metabolism.

FDA Pharmacological Classification · 6 件

L22772Z9CP

LENIOLISIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Phosphoinositide 3-Kinase delta Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 1A2 Inhibitors

Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors

MeSH Pharmacological ClassificationAgents that inhibit PHOSPHOINOSITIDE-3 KINASE activity.
Absorption, Distribution and Excretion · 4 件

The systemic drug exposure (AUC and Cmax) of leniolisib increases dose proportionally. During twice daily dosing approximately 12 hours apart, leniolisib accumulates approximately 1.4-fold (range of 1.0 to 2.2) in achieving steady-state. Steady-state drug concentrations can be expected to be reached after approximately two to three days. The Tmax is about one hour. Food has negligible effects on the systemic exposure of leniolisib.

The mean recovery of total 14C-radioactivity following a single oral dose of 70 mg <sup>14</sup>C-leniolisib was 92.5% following 168 hours post-dose. About 67% and 25.5% of the recovered dose were in feces and urine, respectively. Of the recovered dose in urine, 6.32% was in unchanged parent drug form and the predominant drug-related material.

The systemic decay in leniolisib plasma concentration over time is bi-exponential, indicating a distribution delay toward peripheral tissues. The volume of distribution of leniolisib is estimated to be 28.5 L in patients with APDS.

In one study, healthy volunteers received leniolisib single ascending doses up to 400 mg and multiple ascending doses up to 140 mg twice daily for 14 days. Oral drug clearance from plasma (CL/F) was 4 L/h.

上流・下流製品情報

上流原料

1-Pyrrolidinecarboxylic acid, 3-[[5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]pyrido[4,3-d]pyrimidin-4-yl]amino]-, 1,1-dimethylethyl ester, (3S)-1-Pyrrolidinecarboxylic acid, 3-[[5,6,7,8-tetrahydro-6-(phenylmethyl)pyrido[4,3-d]pyrimidin-4-yl]amino]-, 1,1-dimethylethyl ester, (3S)-1-Pyrrolidinecarboxylic acid, 3-[(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino]-, 1,1-dimethylethyl ester, (3S)-6-ベンジル-4-クロロ-5,6,7,8-テトラヒドロピリド[4,3-D]ピリミジン5-ブロモ-2-メトキシ-3-(トリフルオロメチル)ピリジン2-メトキシ-3-(トリフルオロメチル)ピリジン(3S)-(-)-1-(tert-ブトキシカルボニル)-3-アミノピロリジン2-クロロ-3-(トリフルオロメチル)ピリジンプロピオニルクロリド